Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 11/2002

01-11-2002 | Adis New Drug Profile

Aripiprazole

Authors: Jane K. McGavin, Karen L. Goa

Published in: CNS Drugs | Issue 11/2002

Login to get access

Abstract

▴ Aripiprazole is a quinolinone derivative and the first of a new class of atypical antipsychotics. The drug has partial agonist activity at dopamine D2 and serotonin 5-HT1a receptors, and is also an antagonist at 5-HT2A receptors.
▴ In patients with acute relapse of schizophrenia or schizoaffective disorder, aripiprazole 15 to 30 mg/day was at least as effective as haloperidol 10 mg/day and had similar efficacy to risperidone 6 mg/day in well designed, 4-week, placebo-controlled trials.
▴ Negative symptoms improved earlier in the aripiprazole than the risperidone group. Efficacy of aripiprazole was observed at week 1 in several trials and was sustained throughout the study periods.
▴ Aripiprazole was superior to placebo in a 26-week trial in patients with stable, chronic schizophrenia. In a 52-week trial involving patients with acute relapsing disease, aripiprazole was similar to haloperidol as assessed by time to failure to maintain response and was superior in ameliorating negative and depressive symptoms.
▴ The incidence of extrapyramidal symptoms during aripiprazole therapy was similar to that with risperidone and placebo but lower than with haloperidol.
▴ Compared with placebo, the proportion of patients with increased plasma prolactin levels and QTc prolongation was similar in patients treated with aripiprazole 15 to 30 mg/day but was significantly increased with haloperidol and risperidone.
Literature
1.
Work Group on S chizophrenia. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997 Apr; 154(4 Suppl.): 1–63
2.
Campbell M, Young PI, Bateman DN, et al. The use of atypical antipsychotics in the management of schizophrenia. Br J Clin Pharmacol 1999 Jan; 47: 13–22PubMedCrossRef
3.
Lehman AF. Managing schizophrenia: interventions and outcomes. Dis Manage Health Outcomes 1997 Jun; 1(6): 286–95CrossRef
4.
Blin O. A comparative review of new antipsychotics. Can J Psychiatry 1999 Apr; 44(3): 235–44PubMed
5.
6.
Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302(1): 381–9PubMedCrossRef
7.
Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Eur J Pharmacol 2002; 441: 137–40PubMedCrossRef
8.
McQuade RD, Burris KD, Jordan S, et al. Aripiprazole: a dopamine-serotonin system stabilizer [poster]. XXIII CINP Congress; 2002 Jun 23–27; Montreal
9.
Inoue A, Miki S, Seto M, et al. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 1997Feb 19; 321(1): 105–11PubMedCrossRef
10.
Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacol 1999 Jun; 20(6): 612–27CrossRef
11.
Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptorbinding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacol 1996; 14(2): 87–96CrossRef
12.
Yokoi F, Gründer G, Biziere K, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsycho-pharmacol 2002; 27(2): 248–59CrossRef
13.
Sasa M, Amano T. Unique pharmacological profile of a novel antipsychotic drug, aripiprazole (OPC-14597). CNS Drug Rev 1997; 3(1): 24–33CrossRef
14.
Fujikawa M, Nagashima M, Inoue T, et al. Partial agonistic effects of OPC-14597, a potential antipsychotic agent, on yawning behavior in rats. Pharmacol Biochem Behav 1996 Apr; 53(4): 903–9PubMedCrossRef
15.
Kikuchi T, Uwahodo Y, Tottori K, et al. Behavioral pharmacological studies of OPC-14597, a novel antipsychotic drug: comparison with OPC-4392, clozapine and haloperidol [abstract no. P-507]. Jpn J Pharmacol 1996; 71Suppl. I: 185P
16.
Uwahodo Y, Kikuchi T, Tottori K, et al. Pharmacological profile of OPC-14597, a novel anti-psychotic drug (2): weak extrapyramidal side effects [abstract no. P1-236]. Jpn J Pharmacol 1995; 67Suppl. I: 144P
17.
Hirose T, Nakai S, Uwahodo Y, et al. Influence of aripiprazole (OPC-14597) on the induction of catalepsy and brain dopamine metabolism after chronic treatment: a comparison with haloperidol or risperidone [abstract no. O-82]. Jpn J Pharmacol 2000; 82 Suppl. 1: 62
18.
Nakai S, Hirose T, Uwahodo Y, et al. Catalepsy and striatolimbic dopamine metabolism following chronic aripiprazole, risperidone and haloperidol. Int J Neuropsychopharmacol 2000 Jul; 3Suppl. 1: S97
19.
Cañive JM, Lewine JD, Edgar JC, et al. Spontaneous brain magnetic activity in schizophrenia patients treated with aripiprazole. Psychopharmacol Bull 1998; 34(1): 101–5PubMed
20.
Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following single and multiple oral dose administration. Eur Neuropsychopharmacol 2000 Sep; 10 Suppl. 3: 306–7CrossRef
21.
Mallikaarjun S, Tammara BK, Salazar DE, et al. The effects of hepatic impairment on the pharmacokinetics of aripiprazole [abstract no. TPII-91]. Clin Pharmacol Ther 2002 Feb; 71(2): 66
22.
Mallikaarjun S, Ali MW, Salazar DE, et al. The effects of age and gender on the pharmacokinetics of aripiprazole [abstract no. TPII-90]. Clin Pharmacol Ther 2002 Feb; 71(2): 66
23.
Citrome L, Josiassen R, Bark N, et al. Pharmacokinetics and safety of aripiprazole and concomitant mood stabilizers [abstract no. P.4.E.035]. Int J Neuropsychopharmacol 2002; 5Suppl. 1 (Jun): S187
24.
Citrome L, Josiassen R, Bark N, et al. Pharmacokinetics and safety of aripiprazole and concomitant mood stabilizers [poster]. XXIII CINP Congress; 2002 Jun 23–27; Montreal
25.
Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002 Sep; 63: 1–9CrossRef
26.
Yeung PP, Carson WH, Saha A, et al. Efficacy of aripiprazole, a novel antipsychotic, in schizophrenia and schizoaffective disorder: results of a placebo-controlled trial with risperidone [abstract no. P.2.040]. Eur Neuropsychopharmacol 2001 Oct; 11Suppl. 3: S259–60CrossRef
27.
Daniel DG, Saha AR, Ingenito G, et al. Aripiprazole, a novel antipsychotic: overview of a phase II study result [abstract no. P.01.242]. Int J Neuropsychopharmacol 2000 Jul; 3Suppl. 1: S157
28.
Petrie JL, Saha AR, McEvoy JP. Aripiprazole, a new typical antipsychotic: phase 2 clinical trial result [abstract no. P.2.114]. Eur Neuropsychopharmacol 1997 Sep; 7Suppl. 2: S227CrossRef
29.
Kujawa M, Saha AR, Ingenito GG, et al. Aripiprazole for long-term maintenance treatment of schizophrenia [abstract no. P.4.E.032]. Int J Neuropsychopharmacol 2002 Jun; 5Suppl. l: S186–7
30.
Kujawa M, Saha A, Ingenito G, et al. Aripiprazole for long-term maintenance treatment of schizophrenia [poster]. XXIII CINP Congress; 2002 Jun 23–27; Montreal
31.
Carson WH, Pigott TA, Saha AR, et al. Aripiprazole vs. placebo in the treatment of chronic schizophrenia [abstract no. P.4.E.033]. Int J Neuropsychopharmacol 2002 Jun; 5 Suppl. 1:S187
32.
Carson WH, Pigott TA, Saha AR, et al. Aripiprazole vs placebo in the treatment of stable, chronic schizophrenia [poster]. XXIII CINP Congress; 2002 Jun 23–27; Montreal
33.
Casey D, Saha AR, Ali MW, et al. Switching to aripiprazole monotherapy [abstract no. P.4.E.034]. Int J Neuropsychopharmacol 2002 Jun; 5Suppl. 1: S187
34.
Casey DE, Saha A, Ali M, et al. Switching to aripiprazole monotherapy [poster]. XXIII CINP Congress; 2002 Jun 23–27; Montreal
35.
Lieberman J, Carson WH, Saha AR, et al. Meta-analysis of the efficacy of aripiprazole in schizophrenia [abstract no. P.4.E.031]. Int J Neuropsychopharmacol 2002 Jun; 5Suppl. 1: S186
36.
Lieberman JA, Carson WH, Saha A, et al. Meta-analysis of the efficacy of aripiprazole in schizophrenia [poster]. XXIII CINP Congress; 2002 Jun 23–27; Montreal
37.
Cornblatt B, Kern RS, Carson WH, et al. Neurocognitive effects of aripiprazole vs olanzapine in stable psychosis [poster]. XXIII CINP Congress; 2002 Jun 23–27; Montreal
38.
Cornblatt B, Kern RS, Carson WH, et al. Neurocognitive effects of aripirazole vs olanzapine in stable psychosis [abstract no. P.4.E.027]. Int J Neuropsychopharmacol 2002 Jun; 5Suppl. 1: S185
39.
Stock E, Marder SR, Saha AR, et al. Safety and tolerability meta-analysis of aripiprazole in schizophrenia [poster]. XXIII CINP Congress; 2002 Jun 23–27; Montreal
40.
Stock E, Marder SR, Saha AR, et al. Safety and tolerability meta-analysis of aripiprazole in schizophrenia [abstract no. P.4.E.025]. Int J Neuropsychopharmacol 2002 Jun; 5Suppl. 1: S186
41.
Carson W, Saha AR, Iwamoto R, et al. Meta-analysis of prolactin effects with aripiprazole [poster]. XXIII CINP Congress; 2002 Jun 23–27; Montreal
42.
Carson W, Saha AR, Iwamoto T, et al. Meta-analysis of prolactin effects with aripiprazole [abstract no. P.4.E.028]. Int J Neuropsychopharmacol 2002 Jun; 5Suppl. 1: S186
43.
Stock E, Saha A, Brunell R, et al. Meta-analysis of cardiac safety with aripiprazole [poster]. XXIII CINP Congress; 2002 Jun 23–27; Montreal
44.
Stock E, Marder SR, Saha AR, et al. Safety and tolerability meta-analysis of aripiprazole in schizophrenia [abstract no. P.4.E.029]. Int J Neuropsychopharmacol 2002 Jun; 5Suppl. 1: S186
45.
Jody D, Saha AR, Iwamoto T, et al. Meta-analysis of weight effects with aripiprazole [poster]. XXIII CINP Congress; 2002 Jun 23–27; Montreal
46.
Jody D, Saha AR, Iwamoto T, et al. Meta-analysis of weight effects with aripiprazole [abstract no. P.4.E.030]. Int J Neuropsychopharmacol 2002 Jun; 5Suppl. 1: S186
47.
Saha A, Ali MW, Ingenito GG, et al. Safety and tolerability of aripiprazole at doses higher than 30 mg [abstract no. P.4 E. 026]. Int J Neuropsychopharmacol 2002 Jun; 5Suppl. 1: S185
48.
Metadata
Title
Aripiprazole
Authors
Jane K. McGavin
Karen L. Goa
Publication date
01-11-2002
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 11/2002
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200216110-00008

Other articles of this Issue 11/2002

CNS Drugs 11/2002 Go to the issue

Correspondence

Liquid Risperidone in the Treatment of Psychotic Agitation

Correspondence

The authors’ reply

Review Article

Teratogenic Potential of the Newer Antiepileptic Drugs

Current Opinion

Treatment Research in Bipolar Disorder

Adis New Drug Profile

Aripiprazole

Leading Article

Therapeutic Potential of Kava in the Treatment of Anxiety Disorders